IART Stock Recent News
IART LATEST HEADLINES
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2024.
Brain-computer interface (BCI) technology creates a direct link between the brain's electrical activity and a digital device. This connection can bring a vast range of benefits in assisting, augmenting and repairing human cognitive functions.
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra (IART) is set to recommence the manufacturing of PriMatrix and SurgiMend at its new facility in Braintree, MA.
The company plans on operationalizing this new state-of-the-art facility in the first half of 2026 The company plans on operationalizing this new state-of-the-art facility in the first half of 2026
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Investors need to pay close attention to Integra LifeScience (IART) stock based on the movements in the options market lately.
PRINCETON, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will present at the 2024 Bank of America Healthcare conference on Tuesday, May 14, 2024 at 4:40pm ET.
Examine the evolution of Integra's (IART) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Strong demand for Integra's (IART) diverse portfolio of leading brands and continued successful market adoption of CereLink contributes to its revenues.